{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["H9c2", "calcineurin", "cardiomyocyte hypertrophy", "high glucose", "tropisetron"]], "OtherID": [], "CitationSubset": ["IM"], "InvestigatorList": [], "SpaceFlightMission": [], "GeneralNote": [], "OtherAbstract": [], "PMID": "26945895", "DateCompleted": {"Year": "2017", "Month": "05", "Day": "09"}, "DateRevised": {"Year": "2018", "Month": "12", "Day": "02"}, "Article": {"ArticleDate": [{"Year": "2016", "Month": "03", "Day": "04"}], "ELocationID": ["10.1111/jphp.12522"], "Language": ["eng"], "Journal": {"ISSN": "2042-7158", "JournalIssue": {"Volume": "68", "Issue": "4", "PubDate": {"Year": "2016", "Month": "Apr"}}, "Title": "The Journal of pharmacy and pharmacology", "ISOAbbreviation": "J Pharm Pharmacol"}, "ArticleTitle": "Tropisetron inhibits high glucose-induced calcineurin/NFAT hypertrophic pathway in H9c2 myocardial cells.", "Pagination": {"StartPage": "485", "EndPage": "493", "MedlinePgn": "485-93"}, "Abstract": {"AbstractText": ["Cardiomyocyte hypertrophy is an important structural feature of diabetic cardiomyopathy. Calcineurin/nuclear factor of activated T-cell (NFAT) pathway plays a central role in the pathogenesis of cardiac hypertrophy. The purpose of this study was to investigate the effects of tropisetron, a novel calcineurin inhibitor, on high glucose (HG)-induced cardiomyocyte hypertrophy and its underlying mechanism.", "H9c2 myocardial cells were treated with tropisetron or cyclosporine A 1 h before exposure to HG for 48 h.", "Exposure to HG resulted in enhanced cell size, protein content and atrial natriuretic peptide (ANP) protein expression. HG significantly increased Ca(2+) level, calcineurin expression and nuclear translocation of NFATc4. Both tropisetron and cyclosporine A markedly prevented the hypertrophic characteristic features, calcineurin overexpression and nuclear localization of NFATc4 while intracellular Ca(2+) was not affected.", "Our results showed that tropisetron may have protective effects against HG-induced cardiomyocyte hypertrophy. The mechanism responsible for this beneficial effect seems to be, at least in part, blockade of calcineurin/NFAT signalling pathway."], "CopyrightInformation": "\u00a9 2016 Royal Pharmaceutical Society."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran."}], "LastName": "Asadi", "ForeName": "Firouzeh", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Institute of Medicinal Plants ACECR, Karaj, Iran."}], "LastName": "Razmi", "ForeName": "Ali", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Dehpour", "ForeName": "Ahmad Reza", "Initials": "AR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran."}], "LastName": "Shafiei", "ForeName": "Massoumeh", "Initials": "M"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "J Pharm Pharmacol", "NlmUniqueID": "0376363", "ISSNLinking": "0022-3573"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Calcineurin Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Indoles"}, {"RegistryNumber": "0", "NameOfSubstance": "NFATC Transcription Factors"}, {"RegistryNumber": "0", "NameOfSubstance": "Nerve Tissue Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Nfatc4 protein, rat"}, {"RegistryNumber": "6I819NIK1W", "NameOfSubstance": "Tropisetron"}, {"RegistryNumber": "85637-73-6", "NameOfSubstance": "Atrial Natriuretic Factor"}, {"RegistryNumber": "EC 3.1.3.16", "NameOfSubstance": "Calcineurin"}, {"RegistryNumber": "IY9XDZ35W2", "NameOfSubstance": "Glucose"}, {"RegistryNumber": "SY7Q814VUP", "NameOfSubstance": "Calcium"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Active Transport, Cell Nucleus"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["metabolism"], "DescriptorName": "Atrial Natriuretic Factor"}, {"QualifierName": ["metabolism"], "DescriptorName": "Calcineurin"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Calcineurin Inhibitors"}, {"QualifierName": ["metabolism"], "DescriptorName": "Calcium"}, {"QualifierName": ["metabolism", "pathology", "prevention & control"], "DescriptorName": "Cardiomegaly"}, {"QualifierName": [], "DescriptorName": "Cell Line"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Size"}, {"QualifierName": [], "DescriptorName": "Cytoprotection"}, {"QualifierName": ["metabolism", "pathology", "prevention & control"], "DescriptorName": "Diabetic Cardiomyopathies"}, {"QualifierName": ["toxicity"], "DescriptorName": "Glucose"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Indoles"}, {"QualifierName": ["drug effects", "metabolism", "pathology"], "DescriptorName": "Myocytes, Cardiac"}, {"QualifierName": ["metabolism"], "DescriptorName": "NFATC Transcription Factors"}, {"QualifierName": ["metabolism"], "DescriptorName": "Nerve Tissue Proteins"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": ["drug effects"], "DescriptorName": "Signal Transduction"}, {"QualifierName": [], "DescriptorName": "Tropisetron"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2015", "Month": "8", "Day": "22"}, {"Year": "2016", "Month": "1", "Day": "17"}, {"Year": "2016", "Month": "3", "Day": "7", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "3", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "5", "Day": "10", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["26945895", "10.1111/jphp.12522"]}}], "PubmedBookArticle": []}